Hepatitis Vaccines

4 Drugs classified under this drug class

Hepatitis Vaccines. Hepatitis B Vaccine 10 mcg / 0.5 ml, 20 mcg / 0.5 ml.
10 mcg: PREFILLED SYRINGE: 1, 10, 25, 50.
Birth to 15 yrs, incl. neonates: 10 μg
(0.5 ml) I.M. in deltoid or anterolateral
thigh. 1st dose at elected time, 2nd dose
1 mth. later, 3rd dose 6 mths. aft. 1st
dose.. Accelerated sched.: 1st dose at
elected time, 2nd dose 1 mth. later, 3rd
dose 2 moths. aft. 1st dose. 4th dose 12
mnths. after 1st dose.
20 mcg: MONODOSE VIALS: 1 (with disposable syringe). 25 (with disposable syringes packed separately and avail. on request).
Adults: 20 μg (1 ml) I.M. in deltoid
region. in 3 doses. 1st dose at elected
time. 2nd dose 1 mth. later. 3rd dose 6
mths. aft. 1st dose. Ped: See ENGERIX-B
PED.
Active immun. against hepatitis B virus
infect.
C/I: Hypersen. to thr product or hyperse.
after prev. Hep. B vac., acute severe
febrile illness.

Hepatitis Vaccines. Hepatitis B Vaccine 2.5 mcg/0.5 ml, 5 mcg/0.5 ml, 10 mcg/ml.
VIALS: 1, 25 x 10 μg/ml. Adults/child
over 10 yrs: 1st dose: At elected date;
2nd dose: 1 mth later; 3rd dose: 6 mths
aft. 1st dose. IM into deltoid muscle.
VIALS: 1, 25 x 2.5 μg/0.5 ml. Child: Birth-
10 yrs. Inject IM into deltoid/anterolat.
thigh.
VIALS: 1 x 25 x 5 μg/0.5 ml. Child: Birth-
10 yrs in highly endemic areas: As
above.
Active immunizat. against hepatit B virus
(HBV) infect.
C/I: Hypersens., acute illness, minor
infect. not C/I. Not to be admin IV.

Hepatitis Vaccines. Hepatitis A Virus Antigen (Inactivated) 25 U/0.5 ml, 50 U/ml.
Adult formulat: 50 IU/1 ml; Ped./adolesc.
formulat: 25 IU/0.5 ml.
VIAL + SYRINGE: 1 + 1. 18 yrs and over:
Single 1.0 ml (~50U) dose at elected
date; booster dose 1.0 ml (~50U) 6
mths. later. Ped./Adolesc. 2-17 yrs:
Single 0.5 ml (~25U) dose at elected
date; booster dose 0.5 ml (~25U) 6-18
mths. later. See lit.
Active pre-exposure proph. hepatit. A in 2
yrs and older. Prim. immunizat. to be
given at least 2 wks. prior to expect.
exposure to HIV (see lit.).
C/I: Hypersens.

Hepatitis Vaccines. Human Hepatitis B Immunoglobulin 500 IU.
Sol. for  SC inj. 5 pre-filled syringes of 1ml. In HBV-DNA neg. adlts at least one week after liver transplant.:
- sc inject. per week or fortnightly according to serum anti-HBs trough levels.
Prior to the init. of SC tmt., adequate anti-HBs serum levels should be stabiliz. with an IV hepat. B immunoglobulin to levels at or above 300-500 IU/L in order to ensure adeq. anti-HBs coverage during transit. from IV to SC dosing. Antibody levels >100 IU/L should be maint. in HBsAg and HBV-DNA negat. pts.
Dose can be indiv. establ. and adapt. from 500 IU up to 1,000 IU (in except. cases up to 1,500 IU) SC inject. on a weekly or fortnightly basis, according to the serum anti-HBs concentr. and at the discret. of the physician. Antibody levels >100 IU/L should be maint. Pts must be monit. for serum anti-HBs antibody levels regularly. Serum anti-HBs antibody levels should be meas. at least every 2-4 weeks for at least half a year.
  Prevent. of hepat. B virus (HBV) re-infect. in HBsAg and HBV-DNA negat. adlt pts at least one week after liver transplant. for hepat. B induced liver failure..HBV-DNA negat. status should be confirm. within the last 3 months prior to OLT. Pts should be HBsAg negat. before tmt. start. Concom. use of adeq. virostatic agents should be considered as stand. of hepat. B re-infect. prophylaxis.
C/I: Hypersens. In partic., in very rare cases of IgA defic. when the ptt has antibodies against IgA. Must not be admin. IV.